(Q33405372)

English

A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

chronic idiopathic myelofibrosis

1 reference

based on heuristic

inferred from title

Judith D. Goldberg

object named as

Judith D Goldberg

7

0 references

John Mascarenhas

1

object named as

John Mascarenhas

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Min Lu

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Timmy Li

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Bruce Petersen

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tsivia Hochman

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Vesna Najfeld

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ronald Hoffman

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

21 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

161

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

68-75

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12220

21 January 2018

Improving survival trends in primary myelofibrosis: an international study.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12220

21 January 2018

HDAC inhibitors: clinical update and mechanism-based potential.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12220

21 January 2018

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12220

21 January 2018

Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia*

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12220

21 January 2018

Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12220

21 January 2018

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12220

21 January 2018

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12220

21 January 2018

Janus-activated kinase 2 inhibitors: a new era of targeted therapies providing significant clinical benefit for Philadelphia chromosome-negative myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12220

21 January 2018

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12220

21 January 2018

Identifiers

10.1111/BJH.12220

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33405372&oldid=2182408540"